This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this book Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints, Permissions and Rights Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Venkatesan, A. M. Articles by Corbould, A. Search for Related Content PubMed PubMed Citation Articles by Venkatesan, A. M. Articles by Corbould, A.

Insulin Resistance in Polycystic Ovary Syndrome: Progress and Paradoxes

The Division of Women's Health, The Departments of Medicine and of Obstetrics and Gynecology, Brigham and Women's Hospital, 75 Francis Street, Boston, Massachusetts 02115

ABSTRACT

Over the past 20 years, it has been clearly documented that 1) polycystic ovary syndrome (PCOS) has major metabolic sequelae related to insulin resistance and 2) insulin resistance plays an important role in the pathogenesis of the reproductive abnormalities of the disorder. Women with PCOS are at significantly increased risk of developing type 2 diabetes mellitus (DM). Studies in isolated adipocytes and in cultured skin fibroblasts from PCOS women have demonstrated intrinsic postbinding defects in insulin-mediated glucose metabolism. In fibroblasts, the mitogenic pathway of insulin action is intact, consistent with a selective defect in insulin signaling. While PCOS skeletal muscle is resistant to insulin in vivo, cultured muscle cells have normal insulin sensitivity, consistent with a major role of extrinsic factors in producing insulin resistance in this tissue. Excessive serine phosphorylation of the insulin receptor or downstream signaling proteins may be involved in the pathogenesis of insulin resistance in PCOS. The putative serine kinase is extrinsic to the insulin receptor but its identity is unknown. The explanations for tissue-specific and signaling pathway-specific differences in insulin action in PCOS are unknown but may involve differential roles of insulin receptor substrate (IRS)-1 and IRS-2 in insulin signal transduction.

This article has been cited by other articles:

				A. Veiga-Lopez, J. Moeller, D. Patel, W. Ye, A. Pease, J. Kinns, and V. Padmanabhan Developmental Programming: Impact of Prenatal Testosterone Excess on Insulin Sensitivity, Adiposity, and Free Fatty Acid Profile in Postpubertal Female Sheep Endocrinology, May 1, 2013; 154(5): 1731 - 1742. [Abstract] [Full Text] [PDF]

				H. S. Randeva, B. K. Tan, M. O. Weickert, K. Lois, J. E. Nestler, N. Sattar, and H. Lehnert Cardiometabolic Aspects of the Polycystic Ovary Syndrome Endocr. Rev., October 1, 2012; 33(5): 812 - 841. [Abstract] [Full Text] [PDF]

				S. Franks and L. J. Webber 13.8.1 Ovarian disorders OTM, November 30, 2011; 5(1): med-9780199204854-chapter - med-9780199204854-chapter. [Abstract] [Full Text]

				S. Rice, L. J. Pellatt, S. J. Bryan, S. A. Whitehead, and H. D. Mason Action of Metformin on the Insulin-Signaling Pathway and on Glucose Transport in Human Granulosa Cells J. Clin. Endocrinol. Metab., March 1, 2011; 96(3): E427 - E435. [Abstract] [Full Text] [PDF]

				T. Tao, E. P. Wickham III, W. Fan, J. Yang, and W. Liu Distribution of adiponectin multimeric forms in Chinese women with polycystic ovary syndrome and their relation to insulin resistance Eur. J. Endocrinol., September 1, 2010; 163(3): 399 - 406. [Abstract] [Full Text] [PDF]

				M. Jensterle, A. Janez, B. Mlinar, J. Marc, J. Prezelj, and M. Pfeifer Impact of metformin and rosiglitazone treatment on glucose transporter 4 mRNA expression in women with polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2008; 158(6): 793 - 801. [Abstract] [Full Text] [PDF]

				S. Chakrabarty and M. Nagamani Peripubertal Hyperinsulinemia Upregulates Phosphatidylinositol 3-Kinase/Akt Pathway in Rat Ovaries Reproductive Sciences, March 1, 2008; 15(3): 274 - 284. [Abstract] [PDF]

				E.C. Tok, A. Aktas, D. Ertunc, E.M. Erdal, and S. Dilek Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-{gamma}2 Pro12Ala genotype Hum. Reprod., June 1, 2005; 20(6): 1590 - 1595. [Abstract] [Full Text] [PDF]

				D. Ertunc, E.C. Tok, A. Aktas, E.M. Erdal, and S. Dilek The importance of IRS-1 Gly972Arg polymorphism in evaluating the response to metformin treatment in polycystic ovary syndrome Hum. Reprod., May 1, 2005; 20(5): 1207 - 1212. [Abstract] [Full Text] [PDF]

				S. Rice, N. Christoforidis, C. Gadd, D. Nikolaou, L. Seyani, A. Donaldson, R. Margara, K. Hardy, and S. Franks Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries Hum. Reprod., February 1, 2005; 20(2): 373 - 381. [Abstract] [Full Text] [PDF]

				S. Elsenbruch, S. Hahn, D. Kowalsky, A. H. Offner, M. Schedlowski, K. Mann, and O. E. Janssen Quality of Life, Psychosocial Well-Being, and Sexual Satisfaction in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5801 - 5807. [Abstract] [Full Text] [PDF]

				P. A. Kiely, A. Sant, and R. O'Connor RACK1 Is an Insulin-like Growth Factor 1 (IGF-1) Receptor-interacting Protein That Can Regulate IGF-1-mediated Akt Activation and Protection from Cell Death J. Biol. Chem., June 14, 2002; 277(25): 22581 - 22589. [Abstract] [Full Text] [PDF]